anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect.

The hyperglycemic effect of diazoxide begins within an hour and generally lasts no more than 8 hours in the presence of normal renal function.

Diazoxide decreases the excretion of sodium and water, resulting in fluid retention which may be clinically significant.

The hypotensive effect of diazoxide is usually not marked (see ADVERSE REACTIONS).

Other pharmacologic actions of diazoxide include increased pulse rate; increased serum uric acid levels due to decreased excretion; increased serum levels of free fatty acids’ decreased chloride excretion; decreased para-aminohippuric acid; (PAH) clearance with no appreciable effect on glomerular filtration rate.

The concomitant administration of a benzothiazide diuretic may intensify the hyperglycemic and hyperuricemic effects of diazoxide. In the presence of hypokalemia, hyperglycemic effects are also potentiated.

Diazoxide-induced hyperglycemia is reversed by the administration of insulin or tolbutamide. The inhibition of insulin release by diazoxide is antagonized by alpha-adrenergic blocking agents.

Diazoxide is extensively bound (more than 90%) to serum proteins, and is excreted in the kidneys. The plasma half-life following intravenous administration is 28 ± 8.3 hours. Limited data on oral administration revealed a half-life of 24 and 36 hours in two adults. In four children aged 4 months to 6 years, the plasma half-life varied from 9.5 to 24 hours on long-term oral administration. The half-life may be prolonged following overdosage, and in patients with impaired renal function.
Violent and aggressive behavior as well as disorders related to aggressive behavior are highly common in both adult and juvenile forensic psychiatric patients, and is also present in a subgroup of non-forensic psychiatric in- and out-patients. In order to minimize the risk for future violent offending it is important to intervene in these high-risk populations. Previous research showed that punishment alone is counterproductive for repeated offending behavior. In contrast, treatment was found to have a positive effect on reoffending (i.e., less reoffending). However, although knowledge about the treatment of (forensic) psychiatric patients has increased significantly in recent decades, it is still not fully understood what works for whom under which circumstances. One promising new treatment option is Virtual Reality. A newly developed program in this area is the Virtual Reality Aggression Prevention Training (VRAPT). This training is currently implemented and examined in correctional and forensic psychiatric facilities in the Netherlands and in Sweden. Results from the first randomized controlled trial (RCT) on the effectiveness of the intervention showed that the VRAPT group showed a decrease in some aggressive behaviors at post-test, but not anymore at 3-month follow-up. The purpose of the current feasibility and pilot study is to test VRAPT in a Swiss forensic and non-forensic psychiatric setting, including both adult and juvenile patients, and to gather information needed for the design of a large, international, high-quality, multicenter RCT. The research questions will address the effect of VRAPT on aggressive behavior, state-trait anger expression, stages of motivational change, emotion regulation, and therapeutic alliance. The present investigation will be the first study to include juvenile forensic psychiatric patients as well as to test VRAPT in Switzerland, thereby increasing the generalizability of the research to other populations. Furthermore, it will be the first time VRAPT will be tested in a non-forensic psychiatric sample exhibiting aggressive behaviour. In addition, it will address problem awareness and therapy motivation as possible factors influencing treatment outcome, and address some of the limitations of previous research.
Therapeutics have been identified and developed with are targeted to inhibiting metastasis. These are based on the discovery of an invasion complex which confers the ability of cells, for example tumor cells, to translocate across extracellular matrix barriers, as well as the identification of novel peptides that interact with the invasion complex and regulate it's activity. Whole or partials complexes, or individual molecules of the invasion complex are used to screen for proteins or compounds that interact with the invasion complex. Methods of screening for interacting proteins such as osteopontin, sophin B (SEQ ID NO:1), or compounds are well known in the art, some of which are described below. Once interacting proteins have been identified, they are screened for inhibition, enhancement, or reduction of complex activity. The presence of proteins of the invasion complex on or within cells is indicative of particular diseases or disorders, for example, those characterized by a tumor cell or activated macrophage. Elevated levels of proteins that interact with the invasion complex, such as osteopontin, are also indicative of cancer, and in particular, metastatic cancer. Diagnostic methods, described below, will assist in the identification of subject having, or at risk of developing a disorder associated with aberrant expression of any of the identified proteins that form the invasion complex. Because this invasion complex confers the ability to translocate across matrix barriers, peptides that bind to the complex play a role in regulating metastasis and/or organ specific homing of cancer cells.
The study will be carried out at the Faculty of Nursing and Physiotherapy of the University of Alcalá. A total of 60 subjects with nonspecific chronic neck pain will be selected and randomly assigned into two intervention groups. The first group will perform a somatosensory exercise program and a second group will perform activation and endurance-strength exercises of the deep cervical flexors. The duration of the intervention will be 8 weeks, with 6 sessions of physical therapy and daily home exercise. The variables pain, pressure pain threshold, disability, endurance-strength, proprioception, quality of life, kinesiophobia, quality of sleep and depression will be analyzed. Measurements will be taken pre-treatment, post-treatment and a follow-up at 3 months.
Individuals who served in Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) are reporting histories of traumatic brain injury (TBI) and symptoms associated with post traumatic stress disorder (PTSD). Standard neuropsychological measures are ineffective at distinguishing between TBI and PTSD. This pilot project will examine whether methods from cognitive neuroscience can determine the effects of TBI and/or PTSD on executive function. Executive function includes many aspects of goal-oriented behavior, including the ability to inhibit inappropriate behaviors and thoughts. In the proposed study, the investigators are focusing on inhibitory processing, as it is a core component of executive function. Although both TBI and PTSD compromise executive function and TBI often occurs in the context of a traumatic event, very little research has attempted to disentangle the effects that each of these conditions has on inhibitory control. In addition, the investigators are interested in how disinhibition may be linked to impulsive real-world behaviors, such as suicidal tendencies, which are observed at elevated rates in individuals with TBI as well as those with PTSD. Knowing the ways in which inhibitory functions are compromised in these individuals should aid in the development of appropriate treatments aimed at functional improvement for those with mild TBI, PTSD, or mild TBI+PTSD.
Disclosed are compositions comprising the platelet activation receptor C-type Lectin- like Receptor 2 (CLEC-2), and compositions comprising anti-CLEC-2 antibodies or antibodies that inhibit the interaction of CLEC-2 with podoplanin. Also disclosed are and methods of treating subjects in need thereof, comprising administering to the subject an effective amount of the disclosed compositions. Disclosed are recombinant CLEC-2 polypeptides, nucleic acids, antibodies, and compositions comprising recombinant CLEC-2 polypeptides, nucleic acids and antibodies. CLEC-2, has been found to interact with podoplanin. Recombinant CLEC-2 inhibits platelet aggregation induced by podoplanin- expressing tumor cells or lymphatic endothelial cells. Thus, CLEC-2 is responsible for platelet aggregation induced by endogenously expressed podoplanin on cell surfaces. CLEC- 2 is therefore a physiological target protein of podoplanin and is involved in podoplanin- induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin. Disclosed are methods of treating, for instance, platelet aggregation-related disorders by administering effective amounts of the disclosed compositions to subjects in need thereof.
BACKGROUND: Delayed cerebral ischaemia (DCI) is a major cause of morbidity and mortality after aneurysmal subarachnoid haemorrhage (aSAH). Chemical angioplasty (CA) and transluminal balloon angioplasty (TBA) are used to treat patients with refractory vasospasm causing DCI. Multi-modal monitoring including brain tissue oxygenation (PbtO2) is routinely used at this centre for early detection and management of DCI following aSAH. In this single-centre pilot study, we are comparing these two treatment modalities and their effects on PbtO2.
METHODS: Retrospective case series of patients with DCI who had PbtO2 monitoring as part of their multimodality monitoring and underwent either CA or TBA combined with CA. PbtO2 values were recorded from intra-parenchymal Raumedic NEUROVENT-PTO® probes. Data were continuously collected and downloaded as second-by-second data. Comparisons were made between pre-angioplasty PbtO2 and post-angioplasty PbtO2 median values (4 h before angioplasty, 4 h after and 12 h after).
RESULTS: There were immediate significant improvements in PbtO2 at the start of intervention in both groups. PbtO2 then increased by 13 mmHg in the CA group and 15 mmHg in the TBA plus CA group in the first 4 h post-intervention. This improvement in PbtO2 was sustained for the TBA plus CA group but not the CA group.
CONCLUSION: Combined balloon plus chemical angioplasty results in more sustained improvement in brain tissue oxygenation compared with chemical angioplasty alone. Our findings suggest that PbtO2 is a useful tool for monitoring the response to angioplasty in vasospasm.
Spinal cord injury (SCI) is a severe disabling disease that is characterized by inflammation and oxidative reactions. Tangeretin has been shown to possess significant antioxidant and anti-inflammatory activities. The Keap1/Nrf2 pathway, downstream of the Sesn2 gene, is involved in regulating the inflammation and oxidative response. The main objective of this study was to investigate the effect of tangeretin on SCI and its possible mechanism through cell and animal models. A T9 clamp injury was used for the mouse model and the LPS-induced stimulation of BV-2 cells was used for the cell model. The improvement of motor function after SCI was assessed by open field, swimming, and footprint experiments. The morphological characteristics of mouse spinal cord tissue and the levels of INOS, Sesn2, TNF-α, Keap1, Nrf2, IL-10, and reactive oxygen species (ROS) in vivo and in vitro were measured by several methods including western blotting, qPCR, immunofluorescence, HE, and Nissl staining. In vivo data showed that tangeretin can improve motor function recovery and reduce neuron loss and injury size in mice with SCI. Simultaneously, the in vitro findings suggested that treatment of BV-2 cells with tangeretin after LPS stimulation reduced the production of inflammatory factors and ROS, and could convert BV-2 cells from the M1 to the M2 type. Furthermore, Sesn2 knockout suppressed Keap1/Nrf2, inflammatory factors, ROS levels, and the M1 to M2 transition. Tangeretin can alleviate the inflammation and oxidative response induced by SCI by activating the Sesn2/Keap1/Nrf2 pathway.
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer related death worldwide. Because HCC usually occurs in patients with underlying liver disease, candidates for treatment strategies should be selected based on tumor status and liver function. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, which is widely used for treatment allocation , hepatic resection is considered the treatment of choice for single tumors without macrovascular invasion or extrahepatic spread. These patients are beyond the Milan criteria; liver transplantation is not recommended as the first treatment choice because of the risk of recurrence and the scarcity of donors. Ablative therapies, such as percutaneous ethanol injection and radiofrequency ablation (RFA), rarely achieve complete necrosis in tumors \> 3 cm.

Consequently, hepatic resection is considered the only po tentially curative treatment for these patients. Nevertheless, few patients are candidates for hepatic resection because of associated liver cirrhosis and the risk of inducing postoperative liver decompensation. Although perioperative mortality of hepatic resection in cirrhotic patients has decreased, candidates must be selected carefully to avoid life threatening complications. The lon g term outcome of hepatic resection remains poor, mainly because tumors often recur after resection. Moreove r, s ingle large ( 5cm) tumor showed significantly worse survival than other BCLC stage A, which indicate that single tumor should be differently staged according to their tumor size . For these reasons, whether hepatic resection is the optimal treatment for large single HCCs is a matter of debate.

Yttrium 9 0 radioembolization (Y90) allow s accurate tumor targeting while spa ring surrounding parenchyma, resulting in down staging potential and bridging to transplantation strategies The responsiveness of HCC to radiation, while long recognized, has been limited by nontargeted tissue exposure and radiation injury. With the devel opment of advanced microcatheters and short radius of emission of Y90, single lesions confined to particular liver segment s may now be approached with s uperselective radiotherapy, permitting ablative doses to a confined liver volume. The purpose of this study i s to assess the efficacy and safety of neo adjuvant Therapsphere to down stage in single large ( (\> 5cm , long diameter HCC treated with resection.
The objective of this study was to examine the effects of 8-week clinical Pilates training on disease-specific indices, core stability, and balance in ankylosing spondylitis (AS) patients. AS patients were randomly assigned to either the Pilates group (PG) or control group (CG). The PG participated in Pilates training 3 times a week for 8 weeks. Patients in the CG were instructed to follow a home exercise program 3 times a week for 8 weeks. Assessments were performed before and after the interventions. Outcome measures were disease-specific indices, core endurance, and balance. Disease-specific indices were: Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Bath AS Spinal Mobility Index (BASMI), and the AS Quality of Life (ASqOL) questionnaire. Static core endurance was assessed with trunk flexor, extensor endurance, and lateral side bridge tests, while dynamic core endurance was assessed using modified sit-up test. Balance was assessed with static, dynamic, and single-leg stance postural stability (PS) and limits of stability (LOS) tests using the Biodex Balance System SD.
A composition for preventing and treating Th-1 mediated immune diseases, which contains probiotics strain as an active ingredient is provided to reduce the Th1 immune response by inducing hypo-responsiveness without inducing apoptosis of T-cell and treat Th1 cell-mediated diseases. A pharmaceutical composition and a food composition for treating Th1-mediated immune diseases comprise a probiotics mixture strain as active ingredients. The probiotics mixture strain comprises Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidium, and Streptococus thermophilus. The probiotics mixture strain induces the formation of CD4^+Foxp3^+Tregs, and increases the inhibitor activation of naturally accrring Tregs(CD4^+CD25^+). The Th1-mediated immune diseases are inflammatory diseases, transplantation rejection or autoimmune disease. The Th1 cell synthesizes IL-2(interleukin 2) and IFN-gamma(interferon-gamma) but has the cytokine expression pattern that IL-4, IL-5, IL-10 and IL-13 are not synthesized.
Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
PROBLEM TO BE SOLVED: To obtain a recovering agent of a humoral immunity having an effect for recovering a function of the humoral immunity lowered by a side effect of a medicine such as an anticancer agent by using a lactic bacterium as an active ingredient. SOLUTION: This recovering agent of a humoral immunity includes a lactic bacterium belonging to genus Lactobacillus, genus Bifidobacterium, genus Pediococcus, genus Streptococcus, genus Enterococcus or genus Leuconostoc or its treated material as an active ingredient. The lactic bacterium is preferably used as a heat treated microbial cell body and by blending the one with an additive such as a carrier such as a starch and a lactose, a vehicle, a binder, a disintegrator, a lubricant, a stabilizer and a corrigent, and medicating into a tablet or a granule by a well-known method. The recovering agent is administered in a daily dose of 0.002-0.1g/kg body weight in one or several divided portions to an adult. The recovering agent can be dosed together with another medicine because the lactic bacterium has no side effect.  It is effective in prevention of an infectious disease caused by lowering of a humoral immunity.
Traditional agents such benzodiazepines and propofol have long been used to sedate critically ill patients. Unfortunately, these agents have serious disadvantages that may have a negative impact on patient outcomes. These disadvantages include respiratory depression, prolonged mechanical ventilation, paradoxical agitation, myocardial depression, hypotension, tachyphylaxis, physical dependence, and an unpredictable duration of action following long term infusions. Additionally, concomitant use of an opioid or other analgesic is often required for ICU patients to achieve adequate levels of pain relief, which may also prolong awakening and possibly increase respiratory depression.

Dexmedetomidine may offer a new treatment option that remedies many of the deficiencies of traditional sedatives. This agent would provide for accurate, titratable sedation and analgesia without the concurrent respiratory depression and accumulation common to other agents. It may permit greater patient interaction due to reduced impairment of cognition and may reduce risks associated with opioids due to its analgesia sparing property. Although such a drug may have important benefits for ICU patients requiring sedation for greater than 24 hours, dexmedetomidine is not currently approved for such long-term usage.
Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for completing a short survey ($5 Amazon Gift Card).
Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
In recent years, the survival rate after diagnosis of non small cell lung cancer (NSCLC) has improved with advances in treatment. In terms of 5-year average overall survival (OS) by stage at the time of diagnosis, OS decreases significantly from stage IB to IIIA NSCLC, with 68% for stage IB, 53-60% for stage II, and 36% for stage IIIA. How to optimize the perioperative treatment strategy to reduce postoperative recurrence and prolong the survival of patients has raised great concern in early and mid-stage NSCLC. Radiotherapy combined with immunotherapy is suggested for advanced NSCLC in preclinical basic studies and recent clinical trials. Stereotactic body radiation therapy (SBRT) at 8 Gy × 3 Fx plays an effective immunoregulated role and can further enhance the antitumor immune response promoted by immune checkpoint inhibitors (ICIs). Although little is known about the optimal SBRT dose and fraction pattern, 6 Gy × 5 Fx or 8-9 Gy × 3 Fx have shown effectiveness in clinical studies.
PURPOSE:To enable a diagnosis for possibility and non-possibilities of infection of ATL virus, by employing a reaction in which carrier particles sensitized to an adult T-cell leukocythemia (ATL) or its antigen elements agglutinate in the presence of the ATL virus antibody contained in a human serum infected with the ATL virus. CONSTITUTION:An ATL virus is a kind of retroviruses infected with a human T-cell and it is obtainable by culturing strained cells, such as ML-2, HUT-102, etc., separating a cell from culture liquid, and separating the ATL virus from this cell or culture liquid supernatant. For the carrier particles, those for indirect agglutination reaction may be used, such as, erythrocytes of man, sheep, etc., microorganism fangous bodies, such as fungus Serratio, gelatine particles, polystyrenlatex. Kaolin, carbon powder, etc. Further, to the induced reaction of the ATL virus or its antigen element to the carrier particles the Known method of sensitization of the antigens at large may be applied. And, a method of measuring the ATL virus antibody using this reagent may follow the normal method using the indirect agglutination reaction and thus, measurement of the ATL virus antibody is available with high sensitivity and accuracy.
In the 2nd phase, medical organizations will start to work on a new model with the implementation of problem-oriented multidisciplinary approach and the use of modern rehabilitation technologies. There is planning to use clearly defined criteria for transfer from stage to stage, developed by the professional community. When doctors will be trained program "ICF-reader" will have an opportunity to establish a rehabilitation diagnosis on the basis of the ICF, and the option for ICF assessment using rating scales.
Precise frequency data are not available.

Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.

Nausea and vomiting have been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC. at 1-845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Face-to-face theoretical breastfeeding training and then practical training (breastfeeding techniques, burping, changing diapers, milking by hand or pump, etc.) will be given by the researcher to the mothers and fathers. This training is planned to take 30-45 minutes. Then, an additional 15-30 minutes of father-supported breastfeeding training will be given to fathers. At the end of the training, the "Breastfeeding Booklet" prepared by the researchers will be given to the parents.
Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.